Clinical trials: Seborrheic Keratoses
Seborrheic Keratosis
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with Seborrhoeic Keratosis on…
- Trial name
- NCT01214564
- Testing
- PEP005 (ingenol mebutate) Gel
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Peplin
Seborrheic Keratosis
Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis
This is a first-in-humans adaptive design open label trial to explore the safety and efficacy of SM-020. Multiple dosing cohorts will be enrolled.
- Trial name
- NCT05136144
- Testing
- SM-020
- Where
- El Salvador
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Seborrheic Keratosis
Study of A-101 for the Treatment of Seborrheic Keratosis
The purpose of this study is to evaluate the safety and dose-response of 2 concentrations of A-101 versus a vehicle control in the treatment of seborrheic keratosis.
- Trial name
- NCT02260180
- Testing
- A-101
- Where
- 4 sites in United States
- Volunteers
- 119 people
- Sponsor
- Aclaris Therapeutics, Inc.
Non-Melanoma Skin Cancers
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
Open-Label study evaluating safety and efficacy of SM-020 Gel 1.0% in subjects with Seborrheic Keratoses and Non-Melanoma Skin Cancers (i.e. Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ).
- Trial name
- NCT06409195
- Testing
- SM-020 1% Gel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- DermBiont, Inc.
Seborrheic Keratosis
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.
- Trial name
- NCT02667236
- Testing
- A-101 Solution, Vehicle Solution
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Aclaris Therapeutics, Inc.
Seborrheic Keratosis
An Open-Label Safety Study of A-101 Solution
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
- Trial name
- NCT02667288
- Testing
- A-101 Solution
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Aclaris Therapeutics, Inc.
Lesion Skin, Seborrheic Keratosis
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study
Primary study objective is to evaluate the optimization of Nano-Pulse Stimulation (NPS) energy settings for lesion clearance of Seborrheic Keratosis (SKs) from off-facial areas of healthy adults.
- Conditions
- Lesion Skin, Seborrheic Keratosis, Skin Lesion, Benign Skin Tumor
- Trial name
- NCT04249115
- Testing
- Nano-Pulse Stimulation (NPS)
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Pulse Biosciences, Inc.
Seborrheic Keratosis
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
This study is an open-label study designed to evaluate subject's satisfaction after treatment of seborrheic keratoses with A-101 40%.
- Trial name
- SK-FAN (NCT03487588)
- Testing
- A-101 Topical Solution
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Aclaris Therapeutics, Inc.
Seborrheic Keratosis
A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
This is a randomized, double-blind, vehicle-controlled, parallel group study.
- Trial name
- SK (NCT02667275)
- Testing
- A-101 Solution, Vehicle Solution
- Where
- United States
- Volunteers
- 487 people
- Sponsor
- Aclaris Therapeutics, Inc.
Seborrheic Keratosis (SK)
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
- Trial name
- NCT01986920
- Testing
- A-101 25%, A-101 32.5%, A-101 40%
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Aclaris Therapeutics, Inc.
Seborrheic Keratosis
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101…
- Trial name
- NCT02160626
- Testing
- A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution
- Where
- 5 sites in United States
- Volunteers
- 172 people
- Sponsor
- Aclaris Therapeutics, Inc.
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Seborrheic Keratosis
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.
- Trial name
- NCT03148691
- Testing
- A-101
- Where
- 9 sites in United States
- Volunteers
- 253 people
- Sponsor
- Aclaris Therapeutics, Inc.
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Lesion Skin, Seborrheic Keratosis
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
The primary purpose of this trial is to evaluate Nano-Pulse Stimulation (NPS) to clear or remove Seborrheic Keratosis (SK) lesions from off-facial areas of healthy adult subjects.
- Trial name
- NCT03846531
- Testing
- Nano-Pulse Stimulation (NPS)
- Where
- 4 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pulse Biosciences, Inc.
Seborrheic Keratosis
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial.
- Trial name
- NCT06108024
- Testing
- SM-020 gel 1.0%, Vehicle gel
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- DermBiont, Inc.